CurrentBlue Cross Blue Shield - MassachusettsPolicy 662

Composite tissue allotransplantation (hand and face)

This policy addresses coverage and authorization requirements for composite tissue allotransplantation (reconstructive transplantation) of the hand and/or face for Blue Cross Blue Shield - Massachusetts members across commercial and Medicare products.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyComposite tissue allotransplantation (hand and face)

Policy CodePolicy 662

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization when the procedure is performed inpatient.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

InvestigationalCoverage stance

Precert if inpatientAuthorization

No CPT codesCoding

High (89%)Acute rejection

LimitedEvidence

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not covered — Investigational

Covered when ALL of the following are met:

Investigational coverage stance: Composite tissue allotransplantation of the hand and/or face is considered investigational.

Applies to Commercial and Medicare (HMO and PPO) members as described in policy.

For outpatient settings, this procedure is not a covered service for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO BlueSM, and Medicare PPO BlueSM members. Inpatient procedures require precertification/preauthorization for all products when the procedure is performed in the inpatient setting.

The evidence base for composite tissue allotransplantation of the hand and face is limited to case series, systematic reviews of case series, and a small nonrandomized comparative study. These studies indicate the procedures are technically feasible but involve few patients worldwide and provide insufficient comparative data against the best available alternatives (for example, modern prosthetic devices). Consequently, the evidence is insufficient to determine that composite tissue allotransplantation (face or hand) improves net health outcomes, and the procedure is considered investigational.

Provider Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior Authorization Required

Precertification/preauthorization IS REQUIRED for services described in this policy when the procedure is performed inpatient. Providers must obtain prior authorization before scheduling or performing an inpatient composite tissue allotransplantation (hand and/or face).

Applies to all products when the procedure is performed inpatient
Failure to precertify may result in claim denial or reduced payment

Denial Risk

Outpatient Coverage Restriction

When the procedure is performed outpatient, coverage varies by product. For the products listed below, composite tissue allotransplantation of the hand and/or face is not a covered service when performed outpatient.

Commercial Managed Care (HMO and POS) — Outpatient: Not a covered service
Commercial PPO and Indemnity — Outpatient: Not a covered service
Medicare HMO BlueSM — Outpatient: Not a covered service
Medicare PPO BlueSM — Outpatient: Not a covered service

Documentation Required

Precertification and Coding/Documentation

Providers must report all services using current industry-standard procedure, revenue, and diagnosis codes (CPT, HCPCS, ICD-10), and include appropriate modifiers and documentation. Follow precertification instructions when the procedure is performed inpatient and ensure coding supports the medical necessity and the inpatient admission.

Use the most up-to-date codes and modifiers available at the time of service
Ensure clinical documentation justifies inpatient level of care when authorization is requested

Denial Risk

Investigational Service — Denial Risk

Composite tissue allotransplantation of the hand and/or face is considered investigational. Claims billed for investigational services may be denied consistent with policy and member contract.

Denial risk exists when service is billed as investigational
Refer to the member's contract benefits in effect at the time of service to determine coverage

Clinical Background

Composite tissue allotransplantation, also referred to as vascularized composite allotransplantation, involves transplantation of multiple histologically different tissues such as skin, connective tissue, blood vessels, muscle, bone, and nerve. These reconstructive transplants have been performed primarily for hand and face reconstruction. Procedures are technically complex and lengthy, require multidisciplinary teams, and are undertaken with goals of improving function and psychosocial outcomes rather than being life-saving.

Contraindications and Candidate Requirements

Candidates for hand or face composite tissue allotransplantation must be able to adhere to a lifelong regimen of immunosuppressive drugs and participate in intensive physical therapy after transplant. Extensive medical and psychosocial screening is required because of risks including acute and chronic rejection (reported acute rejection rates as high as 89% in reviews), opportunistic and potentially life-threatening infections, metabolic complications (such as diabetes and kidney damage), increased risk of lymphoma, and the possibility of allograft loss. These risks and the intensive follow-up requirements are contraindications for candidates unable or unwilling to comply with lifelong immunosuppression and the demanding rehabilitation program.

Evaluation and Candidate Screening

Step Therapy

Evaluation and lifelong-care readiness required

Potential recipients must undergo extensive medical and psychosocial screening and be prepared for lifelong immunosuppressive regimens and intensive rehabilitation.

Be able to adhere to lifelong immunosuppression (risks include acute/chronic rejection, opportunistic infections, metabolic disorders, and lymphoma).
Participate in intensive physical therapy and long-term follow-up due to high rates of acute rejection and potential for allograft loss.

Post-Transplant Care and Rehabilitation

Post‑transplant care and rehabilitation

ImmunosuppressionRequires lifelong regimen of immunosuppressive drugs

RehabilitationRequires active participation in intensive physical therapy to restore functionality

Major risksAcute and chronic rejection; review reported overall acute rejection rate of 89% and chronic rejection in 11% of recipients

Other medical risksOpportunistic infections (potentially life‑threatening), metabolic disorders (eg, diabetes, kidney damage), and lymphoma

Functional and psychosocial challengesPotential for limited functional improvement compared with prosthetics, allograft loss requiring further procedures, and psychosocial distress if expectations not met